MACUGEN®
New Treatments - Now Available
Introducing a new treatment for neovascular (wet) age-related macular degeneration (AMD)
The first targeted anti-VEGF* therapy, MACUGEN® (pegaptanib sodium injection) works differently from all other currently available treatments for neovascular (wet) AMD. Evidence shows VEGF is an essential signal in pathologic processes underlying neovascular AMD. Call today 609-877-2800 to learn more or REQUEST A CONSULTATION
What is Macular Degeneration?
Macular Degeneration is the number one cause of legal blindness in people over the age of 60. The most common form is related to aging and is referred to as Age-Related Macular Degeneration (AMD or ARMD).
Risk Factors
Research has not yet uncovered the cause of Macular Degeneration. The disease is frustrating for both patients and doctors because there still are very frew treatment options and no way to prevent the disease.
Macular Degeneration can hide without any obvious symptoms. If the disease affects one eye, your other eye can compensate for the vision loss. This means you may not notice the loss until it becomes very apparent. There are other risk factors besides age that can lead to Macular Degeneration. Your chance of developing the disease more than doubles if you smoke or have smoked in the past 15 years. In addition, research has shown that Caucasians tend to get the disease more often than other races. if you have relatives with Macular Degeneration, you also have a higher risk of developing the disease.
Request a CONSULTATION today.